mbiomics GmbH focuses on developing microbiome-based therapeutics aimed at transforming the treatment of severe and chronic diseases. The company employs proprietary precision analytics and patient insights to create tailored microbial communities that address the unique needs of individual patients. Their approach seeks to harness the gut microbiome's immunological and metabolic capabilities to restore healthy microbial ecosystems, thereby providing a more effective treatment paradigm. By recapitulating the clinical efficacy of fecal transplants through the design of complex microbial consortia, mbiomics aims to enhance safety and disease-specific activity in their therapeutic offerings.

A key technological advantage for mbiomics is their proprietary fluorescence microscopy-based profiling technology, which allows for high-precision, sensitive, and in-depth analysis of the microbiome composition in human samples. This advanced profiling capability enables the rapid and accurate identification of optimal microbial strains for creating complex consortia tailored to specific diseases. The multiplexing panels developed by mbiomics are crucial for informing the selection process, ultimately leading to therapeutics with improved efficacy and safety profiles. This scientific foundation positions mbiomics as a leader in the microbiome therapeutics space, equipped to deliver innovative solutions for patient care.

Germany

We founded mbiomics to improve peoples lives by providing a novel approach to fully understand the secrets of the microbiome with the goal to better inform targeted therapies and how to lead a healthy life.

mbiomics GmbH

Company Details